New cancer drug trial aims to stop tumor growth
Disease control
Recruiting now
This study is testing an experimental immunotherapy called PRL3-Zumab in patients with advanced solid cancers that have spread. The trial aims to see if the treatment can safely slow or stop cancer progression for at least six months. About 52 patients will receive intravenous in…
Phase: PHASE2, PHASE3 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC